JP2024539089A5 - - Google Patents

Info

Publication number
JP2024539089A5
JP2024539089A5 JP2024523403A JP2024523403A JP2024539089A5 JP 2024539089 A5 JP2024539089 A5 JP 2024539089A5 JP 2024523403 A JP2024523403 A JP 2024523403A JP 2024523403 A JP2024523403 A JP 2024523403A JP 2024539089 A5 JP2024539089 A5 JP 2024539089A5
Authority
JP
Japan
Prior art keywords
rrna
modified
molecule
regulatory region
replicase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/078869 external-priority patent/WO2023066874A1/en
Publication of JP2024539089A publication Critical patent/JP2024539089A/ja
Publication of JP2024539089A5 publication Critical patent/JP2024539089A5/ja
Pending legal-status Critical Current

Links

JP2024523403A 2021-10-18 2022-10-17 修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用 Pending JP2024539089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021078828 2021-10-18
EPPCT/EP2021/078828 2021-10-18
PCT/EP2022/078869 WO2023066874A1 (en) 2021-10-18 2022-10-17 Methods for determining mutations for increasing modified replicable rna function and related compositions and their use

Publications (2)

Publication Number Publication Date
JP2024539089A JP2024539089A (ja) 2024-10-28
JP2024539089A5 true JP2024539089A5 (cg-RX-API-DMAC7.html) 2025-10-22

Family

ID=78483247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523403A Pending JP2024539089A (ja) 2021-10-18 2022-10-17 修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用

Country Status (7)

Country Link
US (1) US20250250626A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419708A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539089A (cg-RX-API-DMAC7.html)
CN (1) CN118451194A (cg-RX-API-DMAC7.html)
AU (1) AU2022372325A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234214A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023066874A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
CN122514603A (zh) * 2023-11-02 2026-08-04 安普利特治疗公司 包含经化学修饰的核碱基的反式扩增rna
WO2025129137A1 (en) * 2023-12-14 2025-06-19 Amplitude Therapeutics, Inc. Two-component platform for trans amplifying rna (tarna) vaccination
CN120379688A (zh) * 2024-01-24 2025-07-25 南京金斯瑞生物科技有限公司 一种自复制rna及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119827A1 (en) 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
CN101848936B (zh) 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
AU2018333530B2 (en) * 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
WO2020146690A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
JP2023521662A (ja) * 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン

Similar Documents

Publication Publication Date Title
Morais et al. The critical contribution of pseudouridine to mRNA COVID-19 vaccines
RU2652899C1 (ru) РНК-проводники для подавления репликации вируса гепатита B и для элиминации вируса гепатита B из клетки-хозяина
Perenkov et al. In vitro transcribed RNA-based platform vaccines: past, present, and future
Tusup et al. Design of in vitro transcribed mRNA vectors for research and therapy
JP2021137036A5 (cg-RX-API-DMAC7.html)
JP2010530245A5 (cg-RX-API-DMAC7.html)
US20050112752A1 (en) Method for the purification of alphavirus replicon particles
JP2023509964A5 (cg-RX-API-DMAC7.html)
Wang et al. Recoding of the vesicular stomatitis virus L gene by computer-aided design provides a live, attenuated vaccine candidate
JP2020510426A5 (cg-RX-API-DMAC7.html)
CN118147171B (zh) 具有增强的外源基因表达水平的自扩增mRNA核酸序列
Le Nouën et al. Attenuation of human respiratory viruses by synonymous genome recoding
CN118222588B (zh) 一种减毒型弓形虫疫苗株及其制备方法和在抗肿瘤中的应用
WO2023035372A1 (zh) 一种有限自我复制mRNA分子系统、制备方法及应用
US20230079750A1 (en) Calr and jak2 t-cell receptors
JP2022513718A5 (cg-RX-API-DMAC7.html)
AU2022262341A1 (en) Alphavirus vectors containing universal cloning adaptors
Pereira-Gómez et al. Altering compositional properties of viral genomes to design live-attenuated vaccines
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
Xu et al. From sequence to system: Enhancing IVT mRNA vaccine effectiveness through cutting-edge technologies
JP2024546964A5 (cg-RX-API-DMAC7.html)
CN106754922A (zh) 调控自身增殖的轮状病毒编码的小rna分子
JP2024542126A5 (cg-RX-API-DMAC7.html)
CN120888569A (zh) 一种自复制mRNA疫苗及其制备方法和用途
JP2024529108A5 (cg-RX-API-DMAC7.html)